1. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius
by Gérard Socié, Claudia Schmoor, Wolfgang A. Bethge, Hellmut D. Ottinger, Matthias Stelljes, Axel R. Zander, Liisa Volin, Tapani Ruutu, Dominik A. Heim, Rainer Schwerdtfeger, Karin Kolbe, Jiri Mayer, Johan A. Maertens, Werner Linkesch, Ernst Holler, Vladimir Koza, Martin Bornhäuser, Hermann Einsele, Hans-Jochem Kolb, Hartmut Bertz, Matthias Egger, Olga Grishina, Jürgen Finke, and
Blood
Volume 117(23):
June 9, 2011
©2011 by American Society of Hematology

2. Cumulative incidence of extensive chronic GVHD by treatment groups overall and by prognostic subgroups.
Cumulative incidence of extensive chronic GVHD by treatment groups overall and by prognostic subgroups. (A) Effect of treatment on extensive cGVHD. (B) Treatment effects within prognostic subgroups with regard to cGVHD, analyzed with Cox regression models adjusted for disease status and stem-cell source.
Gérard Socié et al. Blood 2011;117:
©2011 by American Society of Hematology

3. Effect of chronic GVHD on relapse and nonrelapse mortality.
Effect of chronic GVHD on relapse and nonrelapse mortality. (A) Effect of cGVHD (limited and extensive) on relapse effect estimated from Cox model with time-dependent covariate (HR = 0.49, 95% CI, , P = .037). (B) Effect of cGVHD (extensive) on NRM. Effect estimated from Cox model with time-dependent covariate (HR = 2.06, 95% CI, , P = .075).
Gérard Socié et al. Blood 2011;117:
©2011 by American Society of Hematology

4. Split of overall survival probability into probability of survival free of IST and probability of survival under IST. (A) Overall survival probability.
Split of overall survival probability into probability of survival free of IST and probability of survival under IST. (A) Overall survival probability. (B) Probability of survival free of IST. (C) Probability of survival under IST.
Gérard Socié et al. Blood 2011;117:
©2011 by American Society of Hematology

5. Effect of treatment on late bacterial infection.
Effect of treatment on late bacterial infection. Treatment effect estimated from Cox model adjusted for disease status and stem-cell source (HR [ATG-F vs control]= 0.68, 95% CI, , P = .16).
Gérard Socié et al. Blood 2011;117:
©2011 by American Society of Hematology